ARTHUR-D.-LITTLE
27.6.2024 10:01:32 CEST | Business Wire | Press release
Whatever the success of climate change mitigation measures, companies and society will need to adapt to a changing world. To aid business climate change adaptation strategies, Arthur D. Little (ADL)’s Blue Shift Institute today published We’re doomed, now what?, an in-depth report that sets out five potential scenarios for adaptation and highlights relevant technologies to focus on.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627698200/en/
Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation (Graphic: Business Wire)
The report is based on extensive analysis, interviews with over 40 international experts, surveys of business leaders, and was created in close collaboration with the United Nation’s (UN’s) World Intellectual Property Organization (WIPO).
It works on a “+3°C by 2100” outcome for climate change, based on projections by the Intergovernmental Panel on Climate Change (IPCC) and uses this to underpin five potential, non-exclusive scenarios for the future of climate change adaptation:
- Green Communities: A resource-scarce world in which grassroots initiatives flourish, for lack of more ambitious projects; there is a pull towards greater decentralization, circularity, and frugality
- Lonely at the top: Highly concentrated and competitive industries in which market leaders spearhead adaptation to build competitive advantage and keep satisfying consumers, while operating under increasing constraints
- Wild Green West: A creative chaos in which private adaptation initiatives sprout everywhere, fueled by private capital and hype, with no overarching strategy or consistency
- Don’t Look Up: A bleak future in which neither customers nor finance institutions have adjusted to the new climate reality, leaving nothing but quick fixes and crisis management
- Adaptation Surge: A world in which adaptation is the norm and the new currency, resetting expectations, creating new markets and new needs for differentiation, and possibly overengineering
For each of these futures the report outlines the functional expectations and relevant technologies to drive adaptation. Alongside this, it includes “no regret” solutions, enabling technologies, and capabilities that will be vital, whatever the future brings, and that companies should invest in now.
Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “When faced with prospective technology choices, executives often need to address three challenges: complexity, speed and cognition. Adaptation to climate change is no different. It is complex because climate impacts are local, multifactorial and highly variable; and also because there is a myriad of adaptation technologies available. By modeling potential scenarios we aim to cut through this complexity, providing CEOs with a clear guide to the potential technologies that their adaptation will require.”
Dr. Peter Oksen, Senior Program Officer at the World Intellectual Property Organization (WIPO) GREEN, comments: “This report offers a refreshing new angle to climate action, namely that of businesses and their priorities for adapting to a challenging future. It provides the scenario-based context for the technologies outlined by WIPO GREEN, underscoring the essential role of innovation in forging a sustainable future. By detailing the functional expectations and key technologies necessary for adaptation, it highlights the need to integrate technological advancements within our business, economic and policy frameworks to effectively combat climate change.”
We’re doomed, now what? can be accessed here: https://tinyurl.com/4w35xahm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627698200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
